Vaccinex Company Insiders
| VCNX Stock | USD 3.60 0.11 2.96% |
Slightly above 83 percent of all Vaccinex's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Vaccinex suggests that a fairly large number of insiders are very bullish. Vaccinex employs about 37 people. The company is managed by 7 executives with a total tenure of roughly 87 years, averaging almost 12.0 years of service per executive, having 5.29 employees per reported executive.
Vaccinex's Insider Buying Vs Selling
83
Selling | Buying |
Latest Trades
| 2024-08-09 | Albert Friedberg | Acquired 100 @ 4.51 | View | ||
| 2024-08-05 | Albert Friedberg | Acquired 3653 @ 4.6 | View | ||
| 2024-07-31 | Albert Friedberg | Acquired 200000 @ 6.15 | View | ||
| 2024-05-29 | Albert Friedberg | Acquired 957 @ 4.95 | View | ||
| 2024-04-19 | Albert Friedberg | Acquired 282 @ 4.73 | View | ||
| 2023-12-26 | Strydonck Gerald E. Van | Disposed 224 @ 10.08 | View |
Monitoring Vaccinex's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Vaccinex |
Vaccinex's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Vaccinex's future performance. Based on our forecasts, it is anticipated that Vaccinex will maintain a workforce of slightly above 40 employees by December 2024.Vaccinex Management Team Effectiveness
The company has return on total asset (ROA) of (4.9564) % which means that it has lost $4.9564 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.5909) %, meaning that it created substantial loss on money invested by shareholders. Vaccinex's management efficiency ratios could be used to measure how well Vaccinex manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Vaccinex's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 9.20 in 2024, whereas Return On Tangible Assets are likely to drop (5.86) in 2024. At this time, Vaccinex's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 8.9 M in 2024, whereas Non Currrent Assets Other are likely to drop (1.05) in 2024.Common Stock Shares Outstanding is likely to rise to about 486.8 K in 2024, whereas Net Loss is likely to drop (21.1 M) in 2024.
Vaccinex Workforce Comparison
Vaccinex is rated first in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 92.0. Vaccinex totals roughly 37.0 in number of employees claiming about 40% of equities under Health Care industry.
Vaccinex Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vaccinex insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vaccinex's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Vaccinex insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 5.0 | 15 | 3 | 1,395,553 | 275,724 |
| 2024-03-01 | 2.6667 | 16 | 6 | 4,431,798 | 170.00 |
| 2023-12-01 | 2.3333 | 7 | 3 | 7,146,752 | 15,774 |
| 2021-06-01 | 2.2857 | 16 | 7 | 2,375,315 | 9,793,838 |
| 2020-09-01 | 1.6 | 8 | 5 | 1,189,144 | 4,758 |
| 2018-09-01 | 0.4857 | 17 | 35 | 29,950,420 | 45,479,020 |
Vaccinex Notable Stakeholders
A Vaccinex stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vaccinex often face trade-offs trying to please all of them. Vaccinex's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vaccinex's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jill CPA | Chief Officer | Profile | |
| Jill Sanchez | Interim Controller | Profile | |
| MBA CFA | Chief Officer | Profile | |
| Ernest Smith | Senior Officer | Profile | |
| Maurice Zauderer | CEO, CoFounder | Profile | |
| Elizabeth Evans | COO Medicine | Profile | |
| John Leonard | Senior Development | Profile |
About Vaccinex Management Performance
The success or failure of an entity such as Vaccinex often depends on how effective the management is. Vaccinex management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vaccinex management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vaccinex management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (5.58) | (5.86) | |
| Return On Capital Employed | 10.02 | 10.52 | |
| Return On Assets | (5.58) | (5.86) | |
| Return On Equity | 8.76 | 9.20 |
Please note, the imprecision that can be found in Vaccinex's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vaccinex. Check Vaccinex's Beneish M Score to see the likelihood of Vaccinex's management manipulating its earnings.
Vaccinex Workforce Analysis
Traditionally, organizations such as Vaccinex use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vaccinex within its industry.Vaccinex Manpower Efficiency
Return on Vaccinex Manpower
| Revenue Per Employee | 15.4K | |
| Revenue Per Executive | 81.4K | |
| Net Loss Per Employee | 547.3K | |
| Net Loss Per Executive | 2.9M |
Additional Tools for Vaccinex Stock Analysis
When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.